RDIF adds Hyderabad firm, Virchow as manufacturing partner

MUMBAI: Russia’s sovereign wealth fund’s,

Russian Direct Investment Fund

(

RDIF

) and Hyderabad-based Virchow Biotech announced an agreement to produce up to 200 million doses per year of

Sputnik

V.


The technology transfer is expected to be completed in the second quarter of this year, followed by full-scale commercial production of Sputnik V.

Over the last week, RDIF announced production contracts with three domestic manufacturers which will vaccinate over 300 million people with Sputnik V in a year.

Besides, Virchow Biotech’s 200 million doses to vaccinate 100 million people, Stelis Biopharma will roll out 200 million doses, and Gland Pharma, 252 million doses for 126 million people.

Sputnik V has been registered in 54 countries globally with a total population of over 1.4 billion people. Efficacy of Sputnik V is 91.6% as confirmed by the data published in the reputed medical journal,

Lancet

, the release adds.

The vaccine is based on a proven and well-studied platform of human adenoviral vectors, and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots, says a company statement.


Stay informed with the latest Business News on Times of India. Explore the list of Bank Holidays, stay informed about Budget 2025, discover the new Income Tax Slabs, and use the Income Tax Calculator for hassle-free tax planning.

Unlock Investment Potential: Enroll in ET's Stock Valuation Workshop - Batch 3. Secure Your Spot Now!